Codagenix
Latest round
- Series B
Last raised
- Feb 2023
Total raised
- $47M
Investors
- 4
About Codagenix
Codagenix, Inc.Founded in 2011 and headquartered in New York, US, Codagenix, Inc. focuses on designing vaccines and therapeutics that leverage codon deoptimization technology.Codagenix, Inc. specializes in the development of live-attenuated vaccines and viral therapeutics, utilizing a proprietary synthetic biology platform that incorporates codon deoptimization technology. This innovative approach enables the design of precise and stable edits in viral genomes, resulting in products that provide the broad immunity benefits typically associated with live viruses while ensuring enhanced safety, efficacy, and scalability. Codagenix's offerings target infectious diseases and cancer, aiming to address significant global health challenges. The company focuses on delivering timely vaccine solutions and novel cancer therapies through its comprehensive pipelines, which are designed for diverse applications across human health and animal health sectors.Codagenix generates revenue through partnerships and collaborations with various stakeholders in the healthcare and biotechnology fields. The company's business model includes B2B transactions, where they work closely with pharmaceutical companies, research institutions, and animal health organizations to develop and commercialize their vaccine and therapeutic solutions. Revenue is derived from joint development agreements, milestone payments, and potential royalties from successful product commercialization. Specific pricing plans and transaction structures are tailored to each partnership, reflecting the bespoke nature of the products being developed.In February 2023, Codagenix, Inc. The company aims to launch new products targeting infectious diseases and explore new therapeutic avenues in oncology. Additionally, Codagenix plans to expand its market presence in Europe and Asia by the end of 2024, broadening access to its innovative vaccine and therapeutic portfolio.
Who invested in Codagenix
4 investors across 3 rounds
See all investors in Codagenix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Codagenix
Who invested in Codagenix?
Codagenix has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Codagenix raised?
Codagenix has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Codagenix last raise money?
Codagenix's most recent round on record is a Series B, in Feb 2023.
What does Codagenix do?
Codagenix is a biotechnology company.
Where is Codagenix headquartered?
Codagenix is headquartered in New York, US.
Which VCs invest in companies like Codagenix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Codagenix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Codagenix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.